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Purpose: The clinical efficacy of subcutaneous allergen immunotherapy (SCIT) for 
the treatment of patients with severe atopic dermatitis (AD) using house dust mite 
(HDM) extract has been reported. Cyclosporin has been regarded as an effective 
medication for treatment of severe AD. In this study, we investigated a clinical use-
fulness of combined treatment with SCIT and cyclosporin in patients with severe 
AD. Materials and Methods: Nine patients with severe AD and hypersensitivity to 
HDM were treated with a combination of SCIT using HDM extract and cyclosporin 
for 12 months. The primary efficacy outcome was the change in the standardized 
clinical severity scoring system for AD (SCORAD) values, measured at 6 and 12 
months, in comparison with the values at baseline. Daily dose of cyclosporin was de-
creased or discontinued according to the degrees of clinical improvements in indi-
vidual patients. Results: In 8 patients who completed 12 months of treatment, the 
SCORAD values significantly decreased from 71.5±15.5 (mean±SD) at baseline to 
20.4±14.6 at 6 months and 26.3±13.6 at 12 months (Wilcoxon signed-rank test, 
p=0.01), and no significant systemic side effects were observed. Cyclosporin was 
discontinued in 4 of 8 patients within 8 months after starting the combined treatment. 
Conclusion: In this study, combined treatment with SCIT and cyclosporin resulted 
in significant clinical improvements in patients with severe AD. Further studies are 
needed to test the clinical usefulness of this combined treatment for patients with se-
vere AD.
Key Words:    Dermatitis, atopic, allergens, desensitization, cyclosporin, Derma-
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INTRODUCTION
Atopic dermatitis (AD) is a common chronic relapsing inflammatory skin disease 
characterized by itching, dry skin, inflammation and exudation frequently associat-
ed with a personal or familial history of allergic diseases.1 Allergic response to 
common environmental agents (allergen) has been suggested as one of major 
pathogenetic mechanisms responsible for the development and maintenance of 
chronic skin inflammation in patients with AD.2
Current standard medical therapies for AD using topic corticosteroids and/or Allergen Immunotherapy for Severe AD
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dalities for patients with severe AD. 
We hypothesized that combined treatment with SCIT and 
cyclosporin could provide further long-term clinical im-
provements in patients with severe AD by reducing allergic 
inflammation through induction of allergen-specific im-
mune tolerance together with non-specific immune sup-
pression. Here we report results of an uncontrolled pilot 
study in which patients with severe AD and hypersensitivi-
ty to HDM were treated with a combination of SCIT and 
cyclosporin.
MATERIALS AND METHODS
　　　
Patients
Nine patients (4 females and 5 males) between 13 and 36 
years of age (20.7±8.4; mean±SD) with severe recalcitrant 
AD who fulfilled all of the criteria below were included in 
the study (Table 1). The patients showed the typical clini-
cal features of AD compatible with the diagnostic criteria 
for AD, suggested by Hanifin and Rajka.9 In this study, se-
vere recalcitrant AD was defined when clinical conditions 
of the patients had not been effectively controlled by cur-
rent standard medical therapies (topical moisturizers, topi-
cal corticosteroids, topical calcineurin inhibitors, and oral 
antihistamines) and clinical severity scoring system for 
atopic dermatitis (SCORAD) values of the patients were 
greater than 50 as previously described.8,10 All patients 
showed strong positive results on serum-specific IgE anti-
body tests to HDM (≥3.5 kU/L) by CAP-FEIA (Phadia, 
Uppsala, Sweden), and they all provided written informed 
consent. This study was performed in accordance with lo-
topical calcineurin inhibitors are mainly focused on transient 
improvement of inflammation and clinical symptoms, and 
their long-term clinical efficacies are often disappointing to 
both patients and physicians.3 Although a significant number 
of patients with severe AD can be improved by the treatment 
with systemic corticosteroids, cyclosporin, or mycophenolate 
mofetil, the possibility of systemic toxicities from these med-
ications restricts a long-term clinical application.3
Subcutaneous allergen immunotherapy (SCIT) is a treat-
ment of administering gradually increasing doses of aller-
gen to patients with allergic diseases by subcutaneous injec-
tions in order to decrease a hypersensitivity to the allergen 
and thereby reduce clinical symptoms from exposure to the 
allergen.4 The clinical efficacy of SCIT has been proven for 
the treatment of allergic rhinitis, allergic asthma, and Hyme-
noptera hypersensitivity.4,5 It can alter the natural course of 
respiratory allergic diseases, prevent the development of 
new allergen sensitizations, and produce a sustained clinical 
improvement after discontinuation of the treatment.5
Clinical usefulness of SCIT for AD is still controversial.3 
However, an increasing amount of evidence indicates clini-
cal efficacy of SCIT for the treatment of AD.6 SCIT with 
house dust mite (HDM) extract has been shown to be clini-
cally beneficial in patients with severe AD in a randomized 
controlled study.7 However, compliance rate of the above 
randomized study was about 50% at the end of 1 year treat-
ment period.7 The clinical efficacy of SCIT is not satisfac-
tory in some patients with severe AD.7 Recently, we have 
tried combined treatment with SCIT and a histamine-im-
munoglobulin complex in patients with recalcitrant AD to 
improve the clinical efficacy of SCIT.8 However, there are 
needs for further development of additional therapeutic mo-
Table 1. Characteristics of 9 Patients with Severe AD and Hypersensitivity to House Dust Mite Who Received 
the Combined Treatment with Subcutaneous Allergen Immunotherapy and Cyclosporin for 12 Months
Patients
No. Sex Age 
(yrs)
Duration of 
AD (yrs)
Total IgE 
(kU/L)
Specific IgE to 
Dermatophagoides 
pteronyssinus (kU/L)
Specific IgE to 
Dermatophagoides 
farinae (kU/L)
ECP
(ug/L)
1 M 14   3 1,524 32.6 52.6 43.4
2 M 29 11  188 5.7 12.3 10.9
3 M 17 13 3,801 89.7 >100.0 178.0
4 F 13   2  842 61.3 70.5 33.2
5 F 29   3  776 40.1 78.4 126.0
6 M 17 10 >5,000 >100.0 >100.0 6.1
7 F 17 18 3,510 94.0 >100.0 ND
8 M 36 10 3,649 74.9 >100.0 59.4
  9* F 16   3  277 19.2 28.5 27.2
ECP, eosinophil cationic protein; AD, atopic dermatitis; ND, not done.
*One of the 9 patients enrolled in this study was lost to follow-up at 8 months due to noncompliance. Dong-Ho Nahm and Myoung-Eun Kim
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as a maintenance treatment in out-patient clinic. The total 
duration of SCIT was 12 months in this study. 
To improve the clinical efficacy of SCIT for AD, 0.8 mL 
of maintenance concentration of HDM allergen extract was 
mixed directly with the histamine-immunoglobulin com-
plex and the mixture was injected subcutaneously into the 
upper arm at each time scheduled for maintenance treat-
ment as previously reported.8
Standard medical therapies
Standard medical therapies including topical moisturizers, 
topical calcineurin inhibitor, topical corticosteroids, and 
oral antihistamines were maintained throughout the study 
period. Short-term treatment with low-dose oral corticoste-
roids (≤10 mg of prednisolone/day or an equivalent dose of 
other corticosteroids for fewer than 50 days/year) was al-
lowed for the management of acute exacerbations. The tim-
ing, dose, and duration of oral corticosteroid treatment were 
recorded (Table 2).
Cyclosporin treatment
Oral cyclosporin treatment was started with SCIT in the pa-
tients because uncontrolled severe clinical symptoms from 
AD inhibited normal daily life of patients during the stan-
dard medical therapies (Table 2).
The initial dose of cyclosporin was 100 mg/day and the 
dose of cyclosporin was increased to 200 mg/day to control 
the clinical symptoms of AD after 4 weeks if patients tolerat-
ed the dose of cyclosporin without evidences of gastrointesti-
nal, hepatic or renal toxicities. If the clinical symptoms of AD 
cal clinical practice guidelines, and was approved by the in-
stitutional review board.
Preparations for treatment
A HDM allergen extract containing a mixture of Derma-
tophagoides farinae and Dermatophagoides pteronyssinus 
extracts (50 : 50%), which was adsorbed to aluminum hy-
droxide (Novo-Helisen Depot®; Allergopharma Joachim 
Ganzer KG, Reinbeck, Germany) was used. The concentra-
tion of HDM allergen extract for maintenance immunother-
apy was 5,000 therapeutic units/mL according to the manu-
facturer. The histamine-immunoglobulin complex (Green 
Cross PBM, Seoul, Korea) contained 12 mg of human im-
munoglobulin and 0.15 µg of histamine dichloride.
Allergen immunotherapy
In this study, ultra-rush immunotherapy schedule was ap-
plied to shorten the initial build-up phase of SCIT and pro-
vide a rapid onset of clinical efficacy as previously report-
ed.11 All patients received premedications which consisted 
of fexofenadine 120 mg/day and ebastine 10 mg/day during 
the ultra-rush immunotherapy to minimize systemic aller-
gic reactions. For ultra-rush immunotherapy, patients were 
admitted to the hospital, and 0.1 mL, 0.2 mL, 0.4 mL and 0.8 
mL of maintenance concentrations of HDM allergen ex-
tracts were injected subcutaneously to the patients at 2 hour 
intervals for 6 hours, and they were then observed overnight 
for possible developments of delayed-onset systemic reac-
tions. Then, 0.8 mL of maintenance concentration of HDM 
allergen extract was injected subcutaneously once monthly 
Table 2. Dosage and Duration of Medications with Oral Cyclosporin and Oral Corticosteroids in 9 Patients with 
Severe Atopic Dermatitis Who Received the Combined Treatment with Subcutaneous Allergen Immunothera-
py and Cyclosporin for 12 Months
Patients 
No.
Cyclosporin Oral corticosteroid
Duration of 
medication (days/yrs)
Initial dose 
(mg/day)
Last final dose 
(mg/day)
Duration of 
medication
† (days)
Cumulated 
dose
‡ (mg/yrs)
1 365 100 150   0     0
2 365 100 100   0     0
3 365 100   75   7   70
4 235 100     0 45 450
5   30 100     0   0     0
6 218 100     0 10   50
7 365 100 100 30 300
8   30 100     0 15 150
  9* 231 100   75   7   70
*One of the 9 patients enrolled in this study was lost to follow-up at 8 months after the start of treatment periods due to noncompliance. 
†Duration of oral corticosteroids (≤10 mg of prednisolone/day or an equivalent dose of other corticosteroids) administered during 12 
months of the treatment.
‡Cumulated dose of prednisolone or an equivalent dose of other corticosteroids administered during 12 months of the treatment.Allergen Immunotherapy for Severe AD
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istration of 4 mg of chloropeniramine and 5 mg of dexa-
methasone. No other significant systemic side effects were 
observed in the participants.
Clinical efficacy
In 8 patients who completed all 12 months of treatment, the 
SCORAD values decreased significantly from 71.5±15.5 
(mean±SD) at baseline to 20.4±14.6 at 6 months and 26.3± 
13.6 at 12 months (Wilcoxon signed-rank test, p=0.01, at 6 
months and 12 months compared to the baseline) (Table 3, 
Fig. 1). Cyclosporin was discontinued in 4 of 8 patients within 
8 months after starting the combined treatment (Table 2).
A decrease of SCORAD value ≥50% from baseline value 
(clinical improvement of AD ≥50% compared to baseline: 
ADI50) was observed in 6 (75.0%) of 8 patients after 12 
months of treatment (Table 3).
Oral corticosteroids (≤10 mg prednisolone/day or an equiv-
alent dose of other corticosteroids) were administered in 6 
of the 9 patients due to temporary acute exacerbation of AD 
during the treatment period. However, the total duration of 
oral corticosteroid treatment was less than 50 days in each 
patient (Table 2).
DISCUSSION
In this uncontrolled pilot study, combined treatment with 
SCIT and cyclosporin significantly improved the clinical 
severity of patients with severe recalcitrant AD whose clini-
cal conditions had not been effectively controlled by cur-
rent standard medical therapies. In addition, the combined 
treatment was well tolerated in this study and produced no 
were controlled in the patients, we tried to reduce the dosage 
of cyclosporin every 4 weeks according to the therapeutic re-
sponse, and discontinued if the clinical symptoms could be 
controlled by standard medical therapies and SCIT. Liver and 
kidney functions were checked by blood tests at monthly in-
tervals during the cyclosporin treatment. The timing, dose, 
and duration of cyclosporin treatment were recorded.
Assessment of outcomes
The primary efficacy outcome was the change in the SCO-
RAD values, measured at 6 and 12 months, in comparison 
with the values at baseline as previously described.10 
Statistical analysis
The data are expressed as mean±SD. Statistical significance 
of changes in the SCORAD values before and after treatment 
were analyzed using Wilcoxon signed-rank test. A p value of 
less than 0.05 was regarded as statistically significant.
 
RESULTS
 
Compliance and side effects
One of the 9 patients enrolled in the study was lost to fol-
low-up at 8 months after the treatment due to noncompli-
ance (Table 3). The patient did not experience significant 
side effects from the treatments or significant acute exacer-
bation of AD during the treatment. The other 8 patients 
completed 12 months of combined treatment with SCIT 
and cyclosporin. Generalized urticaria was observed in 2 
patients among 9 patients during ultra-rush immunotherapy. 
Urticaria was rapidly resolved following intravenous admin-
Table 3. Change in Clinical Severity of Atopic Dermatitis (SCORAD Values) Measured at 6 and 12 Months in 
Comparison with the Values at Baseline in Patients with Severe Atopic Dermatitis Who Received the Com-
bined Treatment with Subcutaneous Allergen Immunotherapy and Cyclosporin for 12 Months
Patients No.
SCORAD values Changes compare to baseline values (%)
Baseline 6 months 12 months 6 months 12 months
1   51.1 14.4 11.1 -71.8 -78.3
2   56.9   6.4   9.9 -88.8 -82.6
3 100.0 11.6 36.9 -88.4 -63.1
4    82.5   9.3 11.5 -88.7 -86.1
5   71.5 15.7 31.0 -78.0 -56.6
6   78.5 45.7 40.6 -41.8 -48.3
7   65.0 20.0 27.7 -69.2 -57.4
8   66.4 40.1 41.6 -39.6 -37.3
  9*   57.7 21.2 ND -63.3  ND
ND, not done.
*One of the 9 patients enrolled in this study was lost to follow-up at 8 months after the start of treatment periods due to noncompliance. Dong-Ho Nahm and Myoung-Eun Kim
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that a combination of allergen immunotherapy with cyclo-
sporin treatment in patients with severe AD could provide 
both rapid onset of clinical improvement by cyclosporin 
treatment and long-term stabilization of disease activity by 
allergen immunotherapy. Rapid onset of clinical improve-
ment provided by cyclosporin treatment might also improve 
a long-term compliance of allergen immunotherapy in pa-
tients with severe AD. In this study, the combined treatment 
with SCIT and cyclosporin resulted in significant clinical im-
provements in patients with severe AD, and cyclosporin 
treatment could be discontinued in 4 of 8 patients with severe 
AD who completed SCIT for 1 year. These results suggest 
that cycloporin treatment could be a useful adjuvant therapy 
for SCIT in patients with severe AD, like a successful clinical 
application of short-term oral corticosteroid therapy com-
bined with slow-acting anti-rheumatic medications for pa-
tients with rheumatoid arthritis (so called “bridging therapy 
with oral corticosteroid”) to provide fast and sustained clini-
cal improvement.17 Nevertheless, further studies are needed 
to evaluate the clinical usefulness of this combined treatment 
with SCIT and cyclosporin for severe AD.
There are contradictory aspects on the immunological 
mechanisms of therapeutic efficacy of SCIT and cyclospo-
rin treatment for AD. The main mechanism of SCIT was 
suggested as allergen-specific T cell tolerance associated 
with the induction of allergen-specific regulatory T cell.18 
The key immunological mechanism of cyclosporin is an in-
hibition of calcineurin-dependent pathways of T cells and 
subsequent nonspecific suppression of T cells by modulat-
ing cytokine transcription.3 Theoretically, cyclosporin treat-
ment might inhibit immunological changes produced by al-
lergen immunotherapy in patients with AD. In this study, 
cyclosporin treatment could be discontinued in 4 patients 
among 8 patients with severe AD who completed 1 year of 
SCIT. This result suggests that SCIT could provide long-
term clinical improvement even in patients with severe AD 
on cyclosporin treatment. However, the precise immuno-
pharmacological mechanism of this combined treatment 
should be further investigated.
There are limitations of this study in providing clear evi-
dence for clinical efficacy of the new combined treatment. 
Our study can not escape from a criticism on the need of 
randomized placebo-controlled demonstration of the clini-
cal efficacy because significant placebo effects have been 
observed in the previous studies of SCIT in patients with 
AD and HDM hypersensitivity.6,7 In this study, we used three 
types of different therapeutic modalities to improve clinical 
significant systemic side effects.
There have been numerous studies on the clinical effica-
cy of SCIT for the treatment of AD.12 SCIT with HDM ex-
tract has been shown to be clinically beneficial in patients 
with severe AD in a randomized controlled study.7 Howev-
er, the compliance rate of the above randomized study was 
about 50% at the end of 1-year treatment period.7 A signifi-
cant clinical improvement, defined as a decrease of clinical 
severity score for AD values ≥50% from baseline value 
(ADI50), was observed in only 3 (33.3%) of 9 patients with 
severe AD after 12 months of combined treatment with 
SCIT and a histamine-immunoglobulin complex.8 In the 
present study, it was of an interest to observe that significant 
clinical improvement (ADI50) was achieved in 6 (75.0%) of 
8 patients with severe AD who received 12 months of com-
bined treatment with SCIT and cyclosporin. Further studies 
to improve clinical efficacy and compliance of SCIT for the 
treatment of patients with severe AD are needed.
Allergen immunotherapy has been shown to provide a 
long-lasting suppression of hypersensitivity to allergen and 
modify a natural course in patients with respiratory allergic 
diseases.13,14 Currently available medical therapies for AD are 
designed to temporarily improve the clinical symptoms dur-
ing medication.12 Although there have been limited numbers 
of studies on the clinical efficacy of allergen immunotherapy 
for AD, allergen immunotherapy could provide long-term 
stabilization of AD.15 Cyclosporin has been regarded as the 
most effective medication for short-term treatment of severe 
AD because of rapid onset of clinical efficacy.16 Cyclosporin 
is licensed in North America and Germany for the short-term 
treatment of adults with severe AD in whom conventional 
therapy is ineffective or inappropriate.16 However, the possi-
bility of systemic toxicities from cyclosporin frequently lim-
its their long-term clinical application.16 We hypothesized 
Fig. 1. Change in clinical severity of atopic dermatitis (SCORAD values) be-
fore and after combined treatment with subcutaneous allergen immuno-
therapy and cyclosporin for 12 months in 8 patients with severe atopic der-
matitis. Data are expressed as means±standard error of the mean.
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J Allergy Clin Immunol 1998;102:558-62.
5. Pipet A, Botturi K, Pinot D, Vervloet D, Magnan A. Allergen-spe-
cific immunotherapy in allergic rhinitis and asthma. Mechanisms 
and proof of efficacy. Respir Med 2009;103:800-12.
6. Novak N. Allergen specific immunotherapy for atopic dermatitis. 
Curr Opin Allergy Clin Immunol 2007;7:542-6.
7. Werfel T, Breuer K, Ruéff F, Przybilla B, Worm M, Grewe M, et 
al. Usefulness of specific immunotherapy in patients with atopic 
dermatitis and allergic sensitization to house dust mites: a multi-
centre, randomized, dose-response study. Allergy 2006;61:202-5.
8. Nahm DH, Lee ES, Park HJ, Kim HA, Choi GS, Jeon SY. Treat-
ment of atopic dermatitis with a combination of allergen-specific 
immunotherapy and a histamine-immunoglobulin complex. Int 
Arch Allergy Immunol 2008;146:235-40.
9. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. 
Acta Derm Venereol (Stockh) 1980;92(Suppl):44-7. 
10. Oranje AP, Glazenburg EJ, Wolkerstorfer A, de Waard-van der 
Spek FB. Practical issues on interpretation of scoring atopic der-
matitis: the SCORAD index, objective SCORAD and the three-
item severity score. Br J Dermatol 2007;157:645-8. 
11. Kim ME, Kim JE, Sung JM, Lee JW, Choi GS, Nahm DH. Safety 
of accelerated schedules of subcutaneous allergen immunotherapy 
with house dust mite extract in patients with atopic dermatitis. J 
Korean Med Sci 2011;26:1159-64.
12. Buβmann C, Bieber T, Novak N. Systemic therapeutic options for 
severe atopic dermatitis. J Dtsch Dermatol Ges 2009;7:205-19.
13. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for 
asthma. Cochrane Database Syst Rev 2000:CD001186.
14. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Dur-
ham S. Allergen injection immunotherapy for seasonal allergic 
rhinitis. Cochrane Database Syst Rev 2007:CD001936.
15. Czarnecka-Operacz M, Silny W. Specific immunotherapy in atopic 
dermatitis--Four-year treatment in different age and airborne allergy 
type subgroups. Acta Dermatovenerol Croat 2006;14:230-40.
16. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of 
patients with atopic eczema - a systematic review and meta-analy-
sis. J Eur Acad Dermatol Venereol 2007;21:606-19.
17. Kroot EJ, Huisman AM, Van Zeben J, Wouters JM, Van Paassen 
HC. Oral pulsed dexamethasone therapy in early rheumatoid ar-
thritis: a pilot study. Ann N Y Acad Sci 2006;1069:300-6.
18. Akdis CA, Akdis M. Mechanisms of allergen-specific immuno-
therapy. J Allergy Clin Immunol 2011;127:18-27.
19. Krathen RA, Hsu S. Failure of omalizumab for treatment of severe 
adult atopic dermatitis. J Am Acad Dermatol 2005;53:338-40.
20. Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J, 
et al. Efalizumab for severe atopic dermatitis: a pilot study in 
adults. J Am Acad Dermatol 2007;56:222-7.
21. Simon D, Hösli S, Kostylina G, Yawalkar N, Simon HU. Anti-
CD20 (rituximab) treatment improves atopic eczema. J Allergy 
Clin Immunol 2008;121:122-8.
efficacy for the treatment of severe AD which consisted of 
accelerated schedule of SCIT (ultra-rush immunotherapy), 
combined treatment with SCIT and cyclosporin, and com-
bined treatment with SCIT and histamine-immunoglobulin 
complex. Our study also can be subjected to a criticism 
whether additional effect or synergistic effect was produced 
from the above 3 different therapeutic modalities.
The management of severe AD is still a challenging issue 
for both clinicians and patients.3 Recent clinical trials with 
monoclonal antibodies (anti-IgE antibody, anti-activated T 
cell antibody, anti-B cell antibody) for the treatment of se-
vere AD produced conflicting results.19-21 Therefore, there 
are needs for further development of additional therapeutic 
modalities for patients with severe AD. However, develop-
ment of entirely new therapeutic modality for severe AD 
seems to be very difficult in these days because of various 
regulatory restrictions, costs for clinical trials, and/or risks 
of unexpected toxicity during the new drug developments. 
We suggest that trials to combine pre-existing multiple ther-
apeutic modalities could be one way to improve quality of 
life in patients with severe AD.
In this uncontrolled pilot study, combined treatment with 
SCIT and cyclosporin resulted in significant clinical im-
provements in patients with severe AD. Further controlled 
studies are needed to evaluate clinical usefulness of this 
combined treatment for severe AD.
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